COMPARISON

Lanreotide vs Sermorelin

3 attributes held for at least one of the two. 2 differ. Each value carries the register it came from and the date that register was read.

Answer

Lanreotide is authorised or registered in 9 and Sermorelin in 0 of the 10 registers read. Lanreotide: highest phase Phase 4 (after approval). Sermorelin: No trial states a phase. 0 registered trials include both.

States no view on which is preferable, safer or more effective. Not medical advice.

LanreotideSermorelin
Registered trials
differs
125
clinicaltrials.gov · 2026-10-03
27
clinicaltrials.gov · 2026-10-03
FDA label
differs
FDA-approved: Lanreotide Acetate
openfda · 2026-10-03T17:23:44.062Z
Not checked
no record of "fdaLabel" for sermorelin
EU authorisation
Nothing on record
ema read 2026-08-31
Nothing on record
ema read 2026-08-31

SIDE EFFECTS

Most common side effects, each beside its own placebo

Side effectLanreotideplaceboSermorelinplacebo
Diarrhoea19.5%23.6%--
Abdominal pain16.8%15.9%--
Fatigue12.2%14.6%--
Nausea11.0%12.0%--
Vomiting10.8%7.8%--
Headache10.7%9.4%--
Hypertension8.8%5.6%--
Arthralgia8.0%8.2%--
Back pain8.0%10.3%--
Decreased appetite8.0%8.6%--

Trial register Lanreotide: 5 placebo-controlled trials; Sermorelin: 0. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Lanreotide side effects · Sermorelin side effects

LEGAL STATUS

Approval in each country read

CountryLanreotideSermorelinRegister
United StatesFDA-approvedNot on the registerRegulator FDA
European UnionNot on the registerNot on the registerRegulator EMA
United KingdomAuthorisedNot on the registerRegulator MHRA
CanadaAuthorisedNot on the registerRegulator Health Canada
AustraliaRegisteredStatus unknownRegulator TGA
SwitzerlandAuthorisedNot on the registerRegulator Swissmedic
BrazilRegistadoNot on the registerRegulator ANVISA
SerbiaAuthorisedNot on the registerRegulator ALIMS
SingaporeRegisteredNot on the registerRegulator HSA
TurkeyRuhsatliNot on the registerRegulator TITCK

Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.

WEEKLY

Register Watch, weekly

New trials, approvals and enforcement actions. One email a week.